Re:Cognition Health USA has achieved the prestigious GCSA Clinical Trial Site Certification, becoming the first organization to achieve GCSA Certification in both the US and Europe.
 
GCSA certification recognizes sites that are operating to the highest quality global best-practice standards according to an independent assessment.
 
The GCSA Global Quality Standard for Clinical Research Sites was awarded following an independent review, assessment and gap analysis process carried out by the International Accrediting Organization for Clinical Research (IAOCR). The GCSA standard demonstrates excellence in clinical research operations across seven essential areas identified by sponsors and CROs as being critical to the delivery of world-class clinical trials: Feasibility; Study Start-Up and Initiation; Patient Engagement; Study Management, Operations and Close Down; Workforce Process Quality; Site Business Strategy and Governance.
  
“We are thrilled to have achieved the GCSA quality standard and certification – it’s truly a testament to the hard work and dedication of the entire Re:Cognition Health US team,” explains Mostafa Hassan, MBBCH, Director of Clinical Trials, USA at Re:Cognition Health USA. “We are incredibly proud of this accomplishment and are excited about the opportunities this certification opens up for us moving forward. We’re confident that this achievement will further enhance our commitment to excellence in clinical trials and patient care.”
 
The GCSA quality mark provides reassurance to sponsors, CRO’s, staff and ultimately to patients, that these research sites have been independently quality assured against the robust global quality standards that have been developed and ratified by the industry. The quality mark indicates the site is a ‘Trusted Global Partner’ for the delivery of clinical trials.